ANLN Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous pool of TE1 human esophageal squamous cell carcinoma (ESCC) cells carrying targeted disruptions of the ANLN gene. This polyclonal knockout population enables loss-of-function analysis of anillin, avoiding the clonal artifacts associated with single-cell-derived lines. The mix of editing events provides a robust, reproducible system for studying ANLN-dependent phenotypes.
TE1 is an epithelial cell line derived from a human esophageal squamous cell carcinoma and is widely used to investigate invasion, migration, and drug sensitivity in ESCC. Its malignant properties and faithful retention of oncogenic signaling make TE1 a suitable host for knockout studies aimed at elucidating molecular mechanisms of esophageal cancer progression.
ANLN encodes anillin, an actin-binding scaffold protein critical for cytokinesis, linking the contractile ring to the plasma membrane via interactions with F-actin, myosin II, RhoA, ECT2, CIT, and septins. Transcriptional regulation by E2F1 and activation by PI3K/AKT signaling drive ANLN expression, while anillin in turn promotes ??-catenin nuclear translocation and upregulation of MYC and CCND1, thereby enhancing TCF/LEF transcriptional activity. In cancer, ANLN overexpression disrupts actin dynamics and amplifies Wnt/??-catenin signaling, fueling proliferation and invasion.
In ESCC, ANLN is frequently overexpressed and correlates with poor prognosis, making the TE1 knockout model highly relevant for dissecting its roles in malignant epithelial biology. These polyclonal cells enable examination of cytokinesis failure, cytoskeletal reorganization, and downstream signaling perturbations within a genetically varied population that mirrors tumor heterogeneity. Consequently, they serve as a powerful tool for target validation and pathway interrogation.
Typical applications include Western blotting and RT-qPCR to validate ANLN ablation, immunofluorescence for mitotic and actin defects, and functional assays such as proliferation, migration, and invasion tests. Flow cytometry and live-cell imaging can capture cell cycle and cytokinesis dynamics, while xenograft models assess effects on tumor growth and metastasis. For further information, please contact Ascent Research.
